Pathwork's gene expression test for cancer cleared by FDA
This article was originally published in Clinica
Executive Summary
The US FDA has granted 510(k) approval for Pathwork Diagnostics' Tissue of Origin test for determining the origin of uncertain tumours. The diagnostic analyses a tumour's gene expression pattern and compares it with expression patterns of 15 known tumour types, including bladder, breast and colorectal. This enables more appropriate cancer treatments, especially with the advent of targeted therapies for particular tumour types like Herceptin for breast cancer. The test is the first of its kind to receive FDA clearance, Sunnyvale, California-based Pathwork claims. A 545-patient study showed 89% positive agreement (akin to sensitivity) and 99% negative agreement (akin to specificity). The test was previously available as a service through Pathwork's CLIA-certified laboratory.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.